Dr. James M. Wilson
HILS] "Breakthroughs in Genetic Medicine" seminar series- Dr. James Wilson- Wednesday, January 16th
December 4, 2018
The Grousbeck Gene Therapy Center and Harvard Medical School present:
James M. Wilson, MD, PhD
Delivery Challenges of In Vivo
Gene Therapy and Genome Editing
Infectious disease forecast expert Wilson joins DHS
James Wilson brings nationally recognized infectious disease forecast expertise to School of Community Health Sciences
https://www.unr.edu/nevada-today/news/2014/infectious-disease-expert-wilson-hired
August 28, 2014
James Wilson, recently hired to the faculty of the School of Community Health Sciences, is in the process of developing a University-based, national forecasting center for infectious diseases.
Against a backdrop of current news about outbreaks of deadly disease, the University of Nevada, Reno's Division of Health Sciences recently announced that an infectious disease forecasting expert has joined the faculty of the School of Community Health Sciences.
James Wilson, M.D., created an algorithm-based mechanism that forecasts the spread of infectious diseases worldwide and is used by the Centers for Disease Control, Department of Defense and other national agencies with interest in monitoring these developments.
Now, as a University faculty member, Wilson is beginning the process of developing a forecasting center to track the spread of infectious diseases in Nevada. The goal is to accurately forecast the growth of such conditions so that preventative measures may be put in place early on to avoid overloading the health care system and putting a strain on precious resources as physicians and health care institutions strive to catch up following an outbreak.
"We took a page from the science of weather forecasting to do the same for diseases ranging from foot-and-mouth disease to strep throat to plantar warts," Wilson explained. "Using the same processes, we can forecast a variety of medical conditions."
"In public health we are most interested in the prevention of disease, and work such as Dr. Wilson's represents an exciting new frontier for early prevention," Trudy Larson, M.D., director of the University's School of Community Health Sciences, said.
Wilson has been involved with the Ebola response in terms of forecasting the spread of the virus and developing public education as to the disease and preventative measures to be taken against it.
"The forecasting we do is a powerful driver to educate people about these diseases and for patient education. Some may even reconsider their belief system on vaccinations and in that way, we can help people make the right choices," he said.
Wilson chose to move his infectious disease forecasting center to Nevada due to the synergy with the University and the people here.
"It was the spirit of collaboration, the willingness to innovate, the existing faculty expertise and the research capacity of this University," he explained, adding that he will be training students in the relatively new discipline of infectious disease forecasting and early warning and growing the next generation of analysts who may go on to work for the private sector, the government or become physicians and health care providers.
In some cases of "stable" diseases, Wilson's forecasting model is accurate enough that he can tell how many cases of a particular disease will be diagnosed on a certain day of a given year.
Wilson, who carries the title of research associate professor at the School of Community Health Sciences, is a board certified pediatrician and a Fellow of the American Academy of Pediatrics.
He is the founder and executive vice president of AscelBio, a for-profit corporation that provides consulting services to its clients for infectious disease risk assessments, and director of the AscelBio National Infectious Disease Forecast Center.
He is also founder and executive director of Praecipio International, a non-profit corporation dedicated to enhancing and improving international public health and security against biological threats by stimulating collaboration within and offering education to the international, multi-disciplinary humanitarian community. Wilson has served as an infectious-disease advisor to many organizations including the Department of Homeland Security and National Biosurveillance Integration Center, World Health Organization and NASA.
August 28, 2014
https://ascelbio.com/node/page/dengue-fever-data
2020 Update on Gene Therapy for CNS Diseases Dr Jim Wilson 2020 FAST Science Summit
1,088 viewsJan 2, 2021
10
DISLIKE
SHARE
SAVE
2.56K subscribers
https://www.youtube.com/watch?v=3qbqRfrlUdE
https://www.youtube.com/watch?v=cSVxoe2XhaQ
2019 FAST Science Summit, AAV GeneTherapy, Dr. Jim Wilson, UPenn and John Crowley, Amicus
1,078 viewsDec 27, 2019
12
DISLIKE
SHARE
SAVE
2.56K subscribers
SUBSCRIBE
Foundation for Angelman Syndrome Therapeutics presents "Collaborative efforts toward an AAV gene replacement therapy for the treatment of
Angelman syndrome." 2019 FAST Science Summit - Dr Jim Wilson and John Crowley. Information presented at the 2019 FAST Summit and Gala, December 6, 2019.
John Crowley, the father of two children with a rare genetic disorder known as Pompe Disease,
will share his personal journey from drug discovery to the creation of Amicus Therapeutics, a
company focused on treating rare diseases. Amicus Therapeutics has recently partnered
with the University of Pennsylvania for various CNS gene therapy programs. The FAST-funded
Angelman syndrome program will be discussed as part of this collaboration.
BIOGRAPHIES
Jim Wilson, M.D., Ph.D., University of Pennsylvania
Rose H. Weiss Professor and Director, Orphan Disease Center
; Professor of Medicine and Pediatrics
; Director, Gene Therapy Program
; Perelman School of Medicine, University of Pennsylvania
; Advisor and Co-Founder of Scout Bio and Passage Bio; Co-Founder of Surmount Bio
James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he
has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare
diseases and ways to treat them by gene therapy. The Wilson lab identified a new type of vector based on novel isolates
of adeno-associated viruses which have become best in class for gene therapy being used by over 29 companies. More
recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome
editing and mRNA therapy.
John F. Crowley, Chairman, Chief Executive Officer, Amicus Therapeutics
John F. Crowley is the Chairman, President and CEO of Amicus Therapeutics, Inc., a biotechnology company focused on
the development of novel treatments for human genetic diseases. John’s involvement with biotech stems from the 1998
diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a
cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and
CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe
disease (which he credits as ultimately saving his children’s lives.) In 2001, Novazyme merged into Genzyme Corporation
and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President,
Genzyme Therapeutics. John and his family have been profiled in The Wall Street Journal and are the subjects of a book
by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical
Establishment- In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser
and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The
Crowley Family Journey of Strength, Hope and Joy. John is also a commissioned officer in the U.S. Navy Reserve, assigned
to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in
Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University
of Notre Dame Law School and an M.B.A. from Harvard. John is a Henry Crown Fellow at the Aspen Institute. He lives in
Princeton, NJ with his wife, Aileen and their three children, John, Megan and Patrick. John serves on the board of directors
of the National Make A Wish Foundation of America.
Genetic Approaches for Treating Angelman Syndrome
128 viewsJan 4, 2022
2
DISLIKE
SHARE
SAVE
2.56K subscribers
SUBSCRIBE
Jim Wilson, M.D., Ph.D., describes 3 different platforms his team is investigating to treat Angelman syndrome in a murine model. This includes AAV gene replacement, AAV-mediated expression of microRNAs and genome editing.
J Investig Med
. 1998 Dec;46(9):425-9.
The J.I.M. interview. James M. Wilson, MD, PhD
PMID: 9861777
Abstract
Simplicity of concept lies behind the widespread appeal of human gene therapy. A missing or defective gene is safely replaced by a gene that functions normally. Alternatively genes might be used in the laboratory to manufacture essential proteins and enzymes to create gene-based drugs. The idea of using genes to cure genetic diseases is equally appealing to researchers and the public at large precisely because it holds the promise of a real cure. However, as with so many things in clinical research, turning a simple idea into useful medicine has proved to be remarkably difficult. Nonetheless, the opportunity that gene therapy represents remains very real and, within the past decade, hundreds of scientists have become putative gene therapists. Research in gene therapy is booming in academia and industry, with mixed results. James M. Wilson directs the Institute for Human Gene Therapy at the University of Pennsylvania School of Medicine and is president of the 1500 member American Society of Gene Therapy. In an interview with Investigative Medicine, Wilson discusses the state of the art.
Son ?
https://www.linkedin.com/in/jamesmwilsonv/
2022-02-12-linkedin-com-jamesmwilsonv.pdf
2022-02-12-linkedin-com-jamesmwilsonv-img-1.jpg
Jim has a premium account
Jim W. (He/Him)
2nd degree connection
2nd
Healthcare Data Analyst and Pediatrician
Talks about #covid, #intelligence, #nationalsecurity, #pandemicresponse, and #emergencymanagement
Talks about hashtag covid, hashtag intelligence, hashtag nationalsecurity, hashtag pandemicresponse, and hashtag emergencymanagement
Reno, Nevada, United States Contact info
4,506 followers
500+ connections
1 mutual connection: Ben Gilad
1 mutual connection: Ben Gilad
Follow
More
About
About
Dr. James M Wilson is the CEO and Founder of M2 Medical Intelligence, Inc. who specializes in operational health security intelligence, with a focus on the anticipation, detection, and warning of infectious disease crises. He has led the creation of several systems used for the anticipation and detection of infectious disease crises and disasters. Dr. Wilson was the first operations chief of the Department of Homeland Security’s National Biosurveillance Integration Center. Dr. Wilson led the private intelligence teams that provided tracking of H5N1 avian influenza as it spread from Asia to Europe and Africa, detection of vaccine drifted H3N2 influenza in 2007 and in 2014, warning of the 2009 H1N1 influenza pandemic, discovery of the United Nations as the source of the 2010 cholera disaster in Haiti, warning of the 2020 COVID pandemic and several investigations of alleged and confirmed laboratory accidents and biological weapon deployments. Dr. Wilson is a strong advocate for effective and accountable global health security intelligence and the need for credible and balanced threat assessments.
Activity
Activity
4,506 followers
4,506 followers
Follow
Unfortunately, this excellent source of data is no longer reporting publicly. This was an example of "best in class"
#surveillance . The question raised here is one of accuracy and refinement of assessments, not one of questioning whether we have a crisis or whether we should vaccinate children for COVID.
Source link in the comments.
…show more
22
3 comments
#Sweden 's
#COVID experience, revisited. As with Lombardia, notation of reduced high severity
#hospital demand over time. Ongoing monitoring required.
13
1 comment
#hospital demand:
#Italy , revisited. Both the delta and omicron waves have not produced the same degree of demand and disruption to the hospital infrastructure as the initial wave.
24
11 comments
…show more
Johan Hultin, Who Found Frozen Clues to 1918 Virus, Dies at 97
33
1 comment
Experience
Experience
CEO and Founder
CEO and Founder
M2 Medical Intelligence, Inc.
M2 Medical Intelligence, Inc.
Jan 2016 - Present · 6 yrs 2 mos
Jan 2016 - Present · 6 yrs 2 mos
Reno, Nevada
Reno, Nevada
M2 is a provider of medical intelligence services to the healthcare industry.
M2 is a provider of medical intelligence services to the healthcare industry.
Education
ok .. so 1989 , freshman in college... that means born in 1970...
DR. JAMES M WILSON
DIRECTOR OF THE NEVADA MEDICAL INTELLIGENCE CENTER, UNIVERSITY OF NEVADA-RENO
Dr. James M Wilson is the Director of the Nevada Medical Intelligence Center at the University of Nevada-Reno.
Dr. Wilson is a board-certified, practicing pediatrician who specializes in operational medical intelligence, with a focus on the anticipation, detection, and warning of infectious disease crises. He has led the creation of several of the most powerful systems in the world used for anticipation and detection of infectious disease crises and disasters.
Dr. Wilson was the first operations chief of the Department of Homeland Security’s National Biosurveillance Integration Center and worked with the Intelligence Community during the birth of formal health security intelligence in the mid-2000s.
Dr. Wilson led the private intelligence teams that provided warning of the 2009 H1N1 influenza pandemic, discovery of the United Nations as the source of the 2010 cholera disaster in Haiti, and several investigations of alleged and confirmed biological weapon deployments.
Dr. Wilson is a strong advocate for effective and accountable global health security intelligence and the need for credible and balanced threat assessments.
http://www.c4iconf.com/node/333
https://www.fda.gov/media/115993/download
James M. WIlson V ??
https://dl.acm.org/doi/pdf/10.5555/1614025.1614029
MiTAP for SARS detection
This work has been funded, in part, by the Defense Advanced Research Projects Ag